Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 45-50

  Medeiros, Bruno C ^a   Kohrt, Holbrook E ^a   Gotlib, Jason ^a   Coutre, Steven E ^a   Zhang, Bingyang ^a   Arber, Daniel A ^a   Zehnder, James L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; CANCER THERAPY; CLINICAL ARTICLE; COMORBIDITY; DEATH; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LOW DRUG DOSE; MALE; METHYLATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; DACARBAZINE; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84155163830     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22191     Document Type: Article

References (40)

1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology (Hematology Am Soc Hematol Educ Program) 2004; 98-117.
2. Lowenberg B, Downing JR, Burnett A. Acute Myeloid Leukemia. N Engl J Med 1999; 341: 1051-1062.
3. Ries LG, Melbert D, Krapcho M. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. Available at:, based on November 2006 SEER data submission, posted to the SEER web site, 2007. Accessed September 14, 2010.
4. Menzin J, Lang K, Earle et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Int Med 2002; 162: 1597-1603.
5. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002; 43: 1715-27.
6. Tentori L, Graziani G, Gilberti S, et al. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995; 9: 1888-1895.
7. Messinger Y, Reaman GH, Ek O, et al. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia. Leuk Lymphoma 1999; 33: 289-293.
8. Seiter K, Liu D, Loughran T, et al. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002; 20: 3249-3253.
9. Horton TM, Thompson PA, Berg SL, et al. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol 2007; 25: 4922-4928.
10. Brandwein JM, Yang L, Schimmer AD, et al. A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia 2007; 21: 821-824.
11. Baer JC, Freeman AA, Newlands ES, et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993; 67: 1299-1302.
12. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
13. Taverna P, Catapano CV, Citti L, et al. Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 1992; 3: 401-405.
14. Costello JF, Futscher BW, Tano K, et al. Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 1994; 269: 17228-17237.
15. Lenz G, Hutter G, Hiddemann W, et al. Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann Hematol 2004; 83: 628-633.
16. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61: 3225-3229.
17. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990; 87: 5368-5372.
18. Piccioni D, D'Atri S, Papa G, et al. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother. 1995; 7: 224-229.
19. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009; 27: 1262-1267.
20. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-1011.
21. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
22. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia (AML): a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
23. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
25. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haemat 2007; 136: 624-627.
26. Fehniger TA, Uy GL, Trinkaus K, et al. Phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011; 117: 1828-1833.
27. Juliusson G, Billstrom R, Gruber A, et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 2006; 20: 42-47.
28. 6-alkylguanine DNA alkyltransferase levels: studies with blasts of leukemia patients. Ann Oncol 1995; 6: 389-393.
29. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydrxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fir for intensive therapy. Cancer 2007; 109: 1114-1124.
30. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
31. Lubbert M, Ruter B, Claus R, et al. Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic groups of older AML patients. Results of the FR00331 multicenter phase II study. Blood 2007; 110: 300.
32. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
33. Kantarjian H, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28: 549-555.
34. Burnett AK, Russell NH, Kell J, et al. European development of Clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389-2395.
35. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009; 114: 1166-1173.
36. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Bloods 2007; 109: 1387-1394.
37. Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 2010; 376: 2000-2008.
38. Raymond E, Izbicka E, Soda H, et al. Activity of temozolomide against human colony-forming units. Clin Can Res 1997; 3: 1769-1774.
39. Ingold B, Schraml P, Heppner FL, et al. Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE. 2009; 4: e4775.
40. Brandwein J, Kassis J, Leber B, et al. Identification of AML and MDS patients who could potentially benefit from temozolomide therapy: proportion of patients with low methyl guanine methyltransferase (MGMT) expression level. Blood (ASH Annual Meeting Abstracts) 2010; 116: 3985.